Pay in 4 interest-free payments of $5.93 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
In line with this dedication, we are thrilled to announce the addition of two groundbreaking therapies to our repertoire: peptides, including BPC-157, and decompression therapy
Headache in the first 1-2 doses sometimes attributed by community sources to vasodilatory effects
People with chronic obstructive pulmonary disease (COPD) experience long-term oxidative damage and inflammation of lung tissue, which causes airways to constrict, leading to shortness of breath and coughing
About ATTAIN-MAINTAIN trial and ATTAIN clinical trial program ATTAIN-MAINTAIN (NCT06584916) was a 52-week, Phase 3, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of once-daily orforglipron versus placebo for maintenance of body weight reduction in adults with obesity or overweight with weight-related comorbidities who previously completed the SURMOUNT-5 head-to-head trial
